Isomorphic Labs, a Google DeepMind spinout, in talks for a $5 billion raise at a $50 billion valuation; AI drug‑discovery startup raised $2.1 billion in May.
deepmind drug-discovery google startup
| Source: Techmeme | Original article
Alphabet’s Isomorphic Labs, the DeepMind spin‑out focused on AI drug discovery, is seeking roughly $5 billion in new funding at a $50 billion valuation after a $2.1 billion raise in May.
Alphabet’s DeepMind spin‑out Isomorphic Labs is reportedly in talks to secure roughly $5 billion in fresh capital, valuing the AI‑driven drug‑discovery firm at about $50 billion. The fundraising follows a $2.1 billion round closed in May, underscoring the rapid escalation of investor appetite for artificial‑intelligence applications in life sciences.
The infusion would fund the company’s push to accelerate the design of new therapeutics using large‑scale models that predict molecular behavior, a strategy that promises to cut the time and cost of traditional drug development. By leveraging DeepMind’s expertise in deep learning, Isomorphic Labs aims to generate candidate compounds that can move more quickly into pre‑clinical testing, potentially reshaping how pharmaceutical pipelines are built.
The scale of the deal signals that the market sees AI‑enabled drug discovery as a frontier with outsized economic upside, echoing broader expectations that AI could add tens of billions to the economy by 2030. It also places Isomorphic Labs among a handful of AI startups courting multi‑billion‑dollar valuations, raising questions about how quickly the technology can deliver clinically viable products and how regulators will respond to AI‑generated candidates.
Investors and industry watchers will monitor whether the round closes at the reported valuation, which partners may join the financing, and how the capital is allocated across research, talent acquisition and potential collaborations with big‑pharma firms. The next milestone will be the company’s first publicly disclosed drug candidates and any regulatory filings that stem from its AI‑generated pipelines.
Sources
Back to AIPULSEN